CRISPR Therapeutics Quarterly Cash Flow Statement
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRISPR Therapeutics free cash flow
In the quarter ended Jun 30, 2026, CRISPR Therapeutics generated -$83.5 million of operating cash flow and spent $648,000 on capital expenditures. That left free cash flow of -$84.1 million, a free-cash-flow margin of -826.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
CRISPR Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -91.15M | -122.93M | -130.61M | -106.44M | -208.55M | -136.00M | -37.31M | -85.94M | -126.41M | -116.59M | 89.35M | -112.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | -141.76% | — | — | — | — | — |
| Depreciation & Amortization | 4.28M | 4.32M | 5.66M | 4.43M | 4.65M | 4.74M | 4.84M | 4.74M | 4.84M | 4.83M | 4.90M | 4.92M |
| Stock-Based Compensation | 17.32M | 16.32M | 18.08M | 16.60M | 17.61M | 20.21M | 21.95M | 21.54M | 23.67M | 19.41M | 18.42M | 19.97M |
| Change in Working Capital | -2.15M | -13.89M | 23.98M | 12.36M | -15.24M | 56.00M | -23.33M | -38.85M | 11.40M | 211.46M | -203.24M | 53.01M |
| Operating Cash Flow | -83.50M | -108.90M | -92.55M | -84.63M | -113.88M | -53.95M | -50.03M | -106.91M | -95.58M | 109.75M | -96.07M | -39.86M |
| Capital Expenditures | -648.00K | -504.00K | -517.00K | -74.00K | -117.00K | -206.00K | -254.00K | -219.00K | -707.00K | -721.00K | -738.00K | -2.12M |
| Investing Cash Flow | -55.66M | -410.74M | 37.20M | -119.23M | 69.98M | -19.75M | 105.83M | -161.60M | -126.91M | -97.80M | -81.45M | 121.35M |
| Financing Cash Flow | 7.18M | 591.91M | 116.41M | 296.77M | 2.26M | 10.59M | 16.88M | 9.64M | -466.00K | 305.93M | 38.94M | 1.56M |
| Net Change in Cash | -131.97M | 72.24M | 61.06M | 92.88M | -41.56M | -63.07M | 72.59M | -258.80M | -222.95M | 317.88M | -138.53M | 83.00M |
| Free Cash Flow | -84.15M | -109.40M | -93.07M | -84.71M | -114.00M | -54.15M | -50.28M | -107.13M | -96.29M | 109.03M | -96.81M | -41.97M |
This table shows 12 quarterly periods of CRISPR Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRSP's reporting calendar. What is a cash flow statement?